Stay updated with breaking news from Wolf Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Ladies and gentlemen, greetings, and welcome to the Tri Pointe Homes Second Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode.
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
Cholesterol Efflux Mediator™VAR 200 is in phase 2a development to reduce renal cholesterol and lipid accumulation that damages the kidneys' filtration system in patients with glomerular...
Shares of ZyVersa Therapeutics, Inc. (ZVSA) are up 11% on Friday after the announcement that European Patent Office granted a patent (Patent Number EP 2 836 221) for the company's Phase 2a-ready Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease.
Cholesterol Efflux Mediator™ VAR 200 is in phase 2a development to reduce renal cholesterol and lipid accumulation that damages the kidneys' filtration system in patients with glomerular diseases, including diabetic